NKF 2010 Secondary Hyperparathyroidism Coverage

Study Examines Impact of Ergocalciferol on Markers of Bone and Mineral Metabolism

Study Examines Impact of Ergocalciferol on Markers of Bone and Mineral Metabolism

Weekly (50,000 units) and monthly doses (50,000 units) of ergocalciferol treatment does not significantly impact markers of mineral metabolism (MM) in chronic hemodialysis (HD) patients, a study suggests.

Thrice-Weekly Post-Dialysis Cinacalcet A Viable Option

New approach may ease problems with noncompliance, according to researchers.

SHPT Treatment May Have CAC Benefit

SHPT Treatment May Have CAC Benefit

Cinacalcet plus low-dose vitamin D for secondary hyperparathyroidism yielded encouraging results

Polycystic Kidney Disease Affects PTH-Related Mortality

Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients.

Paricalcitol Improves Survival Regardless of Baseline iPTH Levels

Use of paricalcitol for hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) is associated with a significant improvement in survival independent of baseline levels of intact parathyroid hormone (iPTH) compared with patients who have untreated SHPT.

Cinacalcet Plus Low-Dose Vitamin D May Slow CAC Progression

Cinacalcet plus low-dose vitamin D therapy may improve biochemical control of secondary hyperparathyroidism (SHPT) and attenuate progression of coronary artery calcification (CAC) compared with flexible vitamin D therapy alone in hemodialysis (HD) patients.

Paricalcitol-Treated Hemodialysis Patients May Require Less Erythropoietin

Long-term hemodialysis (HD) patients who receive paricalcitol as treatment for secondary hyperparathyroidism (SHPT) may require less erythropoietin than those who receive no SHPT treatment, according to new data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.

Post-Dialysis Dosing of Cinacalcet May Address Noncompliance

Although daily dosing of cinacalcet may be an optimal treatment for secondary hyperparathyroidism (SHPT) compared with other dosing regimens, thrice-weekly post-dialysis dosing may be a viable option when daily dosing is ineffective because of patient noncompliance or other factors.

Low Vitamin D After Renal Transplantation May Be Underrecognized

Low serum 25-hydroxyvitamin D (25 D) levels may be playing a role in bone disease among renal transplant recipients, researchers reported here at the National Kidney Foundation's Spring Clinical Meetings.

Monthly Monitoring of Parathyroid Hormone May Be Optimal

Monthly Monitoring of Parathyroid Hormone May Be Optimal

Monthly rather than quarterly monitoring of parathyroid hormone (PTH) may be better for chronic hemodialysis (HD) patients.

Cinacalcet Effective for Persistent Post-Transplant HPT

Cinacalcet appears to be a safe and effective agent in the long-term management of persistent post renal transplant hyperparathyroidism.

Sign Up for Free e-newsletters